Drug treatment as HIV prevention among women and girls who inject drugs from a global perspective: Progress, gaps, and future directions

Journal of Acquired Immune Deficiency Syndromes

Volumn 69, Issue , 2015, Pages S155-S161

  Springer, Sandra A ^a   Larney, Sarah ^b   Alam Mehrjerdi, Zahra ^b   Altice, Frederick L ^a   Metzger, David ^c,d   Shoptaw, Steven ^e  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d TREATMENT RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

AIDS; Antiretroviral therapy; Buprenorphine; Drug treatment; Extended release naltrexone; HIV; HIV risk behaviors; Injection drug users; MAT; Medication assisted therapy; Methadone; Naltrexone; Women who inject drugs

Indexed keywords

BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; METHADONE; NALTREXONE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AFRICA SOUTH OF THE SAHARA; ARTICLE; AUSTRALIA; CHINA; DRUG DEPENDENCE; FEMALE; HARM REDUCTION; HETEROSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; INDIA; INDONESIA; INFECTION PREVENTION; IRAN; KENYA; MALAYSIA; NAMED GROUPS OF PERSONS; OPIATE ADDICTION; PAKISTAN; PRIORITY JOURNAL; PROSTITUTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RUSSIAN FEDERATION; SOUTH AFRICA; TANZANIA; THAILAND; UKRAINE; UNITED STATES; UNPROTECTED SEX; VIET NAM; VIRUS TRANSMISSION; WOMEN AND GIRLS WHO INJECT DRUG; COMPLICATION; EPIDEMIOLOGY; HEALTH; HEALTH SERVICE; HIV INFECTIONS; ORGANIZATION AND MANAGEMENT; SUBSTANCE ABUSE; THERAPY;

FEMALE; GLOBAL HEALTH; HIV INFECTIONS; HUMANS; SUBSTANCE ABUSE, INTRAVENOUS; UKRAINE; WOMEN'S HEALTH SERVICES;

EID: 84964345319     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000637     Document Type: Article

References (69)

1. UNAIDS. Global Report: UNAIDS Report on the Global AIDS Epidemic 2012. Geneva, Switzerland: UNAIDS; 2012.
2. Gap Report. 2014. Available at: http://www.unaids.org/en/resources/campaigns/2014/2014gapreport/gapreport. Accessed December 13, 2014.
3. Des Jarlais DC, Feelemyer JP, Modi SN, et al. Are females who inject drugs at higher risk for HIV infection than males who inject drugs: an international systematic review of high seroprevalence areas. Drug Alcohol Depend. 2012;124:95-107.
4. Larney S, Mathers BM, Poteat T, et al. Global epidemiology of HIV among women and girls who use and inject drugs: current knowledge and limitations of the data. J Acquir Immune Defic Syndr. 2015;69(SUPPL. 2): S100-S109.
5. Gowing L, Farrell MF, Bornemann R, et al. Oral substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database Syst Rev. 2011:CD004145.
6. Metzger DS, Zhang Y. Drug treatment as HIV prevention: expanding treatment options. Curr HIV/AIDS Rep. 2010;7:220-225.
7. World Health Organization. Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence. Geneva, Switzerland: World Health Organization; 2009.
8. Gowing L, Farrell M, Bornemann R, et al. Substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database Syst Rev. 2008:CD004145.
9. Minozzi S, Amato L, Vecchi S, et al. Oral naltrexone maintenance treatment for opioid dependence. Cochrane database Syst Rev. 2011: CD001333.
10. Di Paola A, Lincoln T, Skiest DJ, et al. Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for HIV-infected, opioid dependent prisoners and jail detainees who are transitioning to the community. Contemp Clin Trials. 2014;39:256-268.
11. Ferri M, Davoli M, Perucci CA. Heroin maintenance for chronic heroin dependents. Cochrane Database Syst Rev. 2005:CD003410.
12. Mathers BM, Degenhardt L, Ali H, et al. HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. Lancet. 2010;375:1014-1028.
13. World Health Organization. Global Update on the Health Sector Response to HIV, 2014. Geneva, Switzerland: World Health Organization; 2014.
14. Degenhardt L, Mathers BM, Wirtz AL, et al. What has been achieved in HIV prevention, treatment and care for people who inject drugs, 2010-2012? A review of the six highest burden countries. Int J Drug Policy. 2014;25:53-60.
15. Ministry of Health of the People's Republic of China, Joint United Nations Program on HIV/AIDS, World Health Organization. 2011 Estimates for the HIV/AIDS Epidemic in China. Beijing, China; 2011.
16. Li J, Wang C, McGoogan JM, et al. Human resource development and capacity-building during China's rapid scale-up of methadone maintenance treatment services. Bull World Health Organ. 2013;91:130-135.
17. Liu E, Rou K, McGoogan JM, et al. Factors associated with mortality of HIV-positive clients receiving methadone maintenance treatment in China. J Infect Dis. 2013;208:442-453.
18. Malaysian Ministry of Health. Global AIDS response country progress report: January 2010 to December 2011. In: HIV/STI Section DCD, ed. Kuala Lumpur, Malaysia: Malaysia Ministry of Health; 2012.
19. Bazazi AR, Zelenev A, Fu JJ, et al. High prevalence of non-fatal overdose among people who inject drugs in Malaysia: correlates of overdose and implications for overdose prevention from a cross-sectional study. Int J Drug Policy. 2014;pii:S0955-3959(14)00334-X.
20. Mathers BM, Degenhardt L, Phillips B, et al. Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. Lancet. 2008;372:1733-1745.
21. Aceijas C, Friedman SR, Cooper HL, et al. Estimates of injecting drug users at the national and local level in developing and transitional countries, and gender and age distribution. Sex Transm Infect. 2006;82 (suppl 3):iii10-iii17;.
22. Mendelevich V, Zohrabyan V. Access to Health Care Services for Women Who Inject Drugs. UNAIDS; 2012.
23. Krupitsky E, Nunes EV, Ling W, et al. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet. 2011;377:1506-1513.
24. UNAIDS. Global Report: UNAIDS Report on the Global AIDS Epidemic, 2010. Geneva, Switzerland: Joint United Nations Programme on HIV/AIDS (UNAIDS); 2010.
25. Balakireva O, Bondar T, Sereda Y, et al. Analytical Report. Behavior Monitoring and HIV Prevalence Among Injection Drug Users as a Component Second Generation Sentinel Surveillance (Based on Results of the 2011 Biobehavioral Survey). Kyiv, Ukraine: AIDS Alliance; 2012.
26. Ministry of Health of Ukraine (MOH). Ukrainian centre of the control over socially dangerous diseases. In: disases Ioeai, ed. Kyiv, Ukraine: Ministry of Health of Ukraine; 2014.
27. Friedman S, Curtis R, Neagus A, Des Jarlais D. Social Networks, Drug Injector's Lives and HIV/AIDS. New York, NY: Kluwer Academic Publishers; 2002.
28. El-Bassel N, Terlikbaeva A, Pinkham S. HIV and women who use drugs: double neglect, double risk. Lancet. 2010;376:312-314.
29. Booth RE, Lehman WE, Brewster JT, et al. Gender differences in sex risk behaviors among Ukraine injection drug users. J Acquir Immune Defic Syndr. 2007;46:112-117.
30. Corsi KF, Dvoryak S, Garver-Apgar C, et al. Gender differences between predictors of HIV status among PWID in Ukraine. Drug Alcohol Depend. 2014;138:103-108.
31. Alistar SS, Owens DK, Brandeau ML. Effectiveness and cost effectiveness of expanding harm reduction and antiretroviral therapy in a mixed HIV epidemic: a modeling analysis for Ukraine. PLoS Med. 2011;8: e1000423.
32. Filippovych S. Impact of armed conflicts and warfare on opioid substitution treatment in Ukraine: responding to emergency needs. Int J Drug Policy. 2015;26:3-5.
33. Lansky A, Finlayson T, Johnson C, et al. Estimating the number of persons who inject drugs in the United States by meta-analysis to calculate national rates of HIV and hepatitis C virus infections. PloS One. 2014;9:e97596.
34. Oster AM, Sternberg M, Nebenzahl S, et al. Prevalence of HIV, sexually transmitted infections, and viral hepatitis by urbanicity, among men who have sex with men, injection drug users, and heterosexuals in the United States. Sex Transm Dis. 2014;41:272-279.
35. Broz D, Wejnert C, Pham HT, et al HIV infection and risk, prevention, and testing behaviors among injecting drug users-National HIV Behavioral Surveillance System, 20 U.S. cities, 2009. MMWR Surveill Summ. 2014;63:1-56.
36. Springer SA, Spaulding AC, Meyer JP, et al. Public health implications for adequate transitional care for HIV-infected prisoners: five essential components. Clin Infect Dis. 2011;53:469-479.
37. D'Aunno T, Pollack HA, Jiang L, et al. HIV testing in the nation's opioid treatment programs, 2005-2011: the role of state regulations. Health Serv Res. 2014;49:230-248.
38. Rowan-Szal GA, Chatham LR, Joe GW, et al. Services provided during methadone treatment. A gender comparison. J Subst Abuse Treat. 2000; 19:7-14.
39. Chatham LR, Hiller ML, Rowan-Szal GA, et al. Gender differences at admission and follow-up in a sample of methadone maintenance clients. Subst Use Misuse. 1999;34:1137-1165.
40. Hernandez-Avila CA, Rounsaville BJ, Kranzler HR. Opioid-, cannabis-and alcohol-dependent women show more rapid progression to substance abuse treatment. Drug Alcohol Depend. 2004;74:265-272.
41. SAMHSA. National Survey of Substance Abuse Treatment Services (N-SSATS): 2012. Data on Substance Abuse Treatment Facilities. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2013.
42. Available at: http://ni.unimelb.edu.au/-data/assets/pdf-file/0008/464966/Research-Brief-Number-2-Female-IDUsers-Vietnam.pdf.
43. Joint United Nations Programme on HIV/AIDS (UNAIDS). The Gap Report. Geneva, Switzerland. 2014. Available at: http://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2014/unaids-gap-report-en.pdf. Accessed August 24, 2014.
44. Mokri A. Brief overview of the status of drug abuse in Iran. Arch Iran Med. 2002;5:184-190.
45. Tavakoli M, Mohammadi L, Yarmohammadi M, et al. Status and trend of substance abuse and dependence among Iranian women. J Rehabil. 2014; 14:30-37.
46. Haghdoost AA, Sajadi L, Osooli M, et al. HIV bio-behavioral surveillance survey among female sex workers in I. R. Iran in 2010. 2012; Available at: http://www.unaids.org/en/⋯/countryprogressreports/2014countries. Accessed December 19, 2014.
47. Iranian Ministry of Health and Medical Education. AIDS Progress Report of Iran 2014. 2014; Available at: http://www.unaids.org/en/⋯/countryprogressreports/2014countries. Accessed November 18, 2014.
48. Fahimfar N, Sedaghat A, Hatami H, et al. Counseling and harm reduction centers for vulnerable women to HIV/AIDS in Iran. Iran J Public Health. 2013;42:98-104.
49. Razzaghi E, Rahimi Movaghar A, Hosseni M, et al. Rapid situation assessment (RSA) of drug abuse in Iran (1998-1999). 2000; Available at: es.unrol.org/files/RSA2000SUMMARY[1].pdf. Accessed January 23, 2014.
50. Alam-mehrjerdi Z, Noori R, Dolan K. Opioid use, treatment and harm reduction services: the first report from the Persian Gulf region. J Subst Use. 2014;1-7. doi:10.3109/14659891.2014.966344.
51. United Nations Office on Drugs and Crime. Drug use in Pakistan. In: United Nations Office on Drugs and Crime, ed; 2013.
52. Global AIDS Report of Pakistan. 2014. Available at: http://www.unaids.org/en/⋯/countryprogressreports/2014countries. Accessed December 19, 2014.
53. Degenhardt L, Whiteford HA, Ferrari AJ, et al. Global burden of disease attributable to illicit drug use and dependence: findings from the Global Burden of Disease Study 2010. Lancet. 2013;382: 1564-1574.
54. Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2224-2260.
55. Australian Needle and Syringe Program National Data Report 2009-2013. The Kirby Institute, University of New South Wales; 2014. Available at: https://kirby.unsw.edu.au/sites/default/files/hiv/resources/ANSPS-NDR-2009-2013-2.pdf. December 19, 2014.
56. Madden A, Wodak A. Australia's response to HIV among people who inject drugs. AIDS Educ Prev. 2014;26:234-244.
57. Stafford J, Burns L. Findings from the Illicit Drug Reporting System (IDRS). Sydney, Australia. Volume 109. 2014. https://ndarc.med.unsw.edu.au/sites/default/files/ndarc/resources/National-IDRS-2013.pdf
58. Australian Institute of Health and Welfare. National Opioid Pharmacotherapy Statistics Annual Data Collection. Canberra, Australia: Australian Institute of Health and Welfare; 2014.
59. Gisev N, Degenhardt L, Larney S, et al. A comparative study of opioid substitution therapy utilisation among opioid-dependent men and women. Drug Alcohol Rev. 2014;33:499-505.
60. Degenhardt L, Charlson F, Mathers B, et al. The global epidemiology and burden of opioid dependence: results from the global burden of disease 2010 study. Addiction. 2014;109:1320-1333.
61. Pinkham S, Stoicescu C, Myers B. Developing effective health interventions for women who inject drugs: key areas and recommendations for program development and policy. Adv Prev Med. 2012:1-10.
62. Obasanjo O. Not Just in Transit: Drugs, The State and Society in West Africa. West Africa Commission on Drugs; 2014.
63. Global HIV/AIDS Respone: Epidemic Update and Health Sector Progress Towards Universal Access Progress Report 2011. World Health Organization; 2011.
64. Harm Reduction International. The Global State of Harm Reduction 2012: Towards an Integrated Response. London, United Kingdom: Harm Reduction International; 2012.
65. National AIDS Commission Indonesia. Country report on the follow-up to the declaration of commitment on HIV/AIDS. Publisher: National AIDS Commission Indonesia. Jakarta, Indonesia 2008.
66. Safren SA, Wingood G, Altice FL. Strategies for primary HIV prevention that target behavioral change. Clin Infect Dis. 2007;45(SUPPL. 4): S300-S307.
67. Pinkham S, Stoicescu C, Myers B. Developing effective health interventions for women who inject drugs: key areas and recommendations for program development and policy. Adv Prev Med. 2012;2012: 269123.
68. El-Bassel N, Witte SS, Gilbert L, et al. The efficacy of a relationship-based HIV/STD prevention program for heterosexual couples. Am J Public Health. 2003;93:963-969.
69. Strathdee SA, Abramovitz D, Lozada R, et al. Reductions in HIV/STI incidence and sharing of injection equipment among female sex workers who inject drugs: results from a randomized controlled trial. PLoS One. 2013;8:e65812.